Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01607957
Registration number
NCT01607957
Ethics application status
Date submitted
24/05/2012
Date registered
30/05/2012
Date last updated
4/06/2020
Titles & IDs
Public title
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Query!
Scientific title
Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
Query!
Secondary ID [1]
0
0
2012-000109-66
Query!
Secondary ID [2]
0
0
TPU-TAS-102-301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RECOURSE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Colorectal Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Bowel - Back passage (rectum) or large bowel (colon)
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - TAS-102
Treatment: Drugs - Placebo
Experimental: TAS-102 -
Placebo Comparator: Placebo -
Treatment: Drugs: TAS-102
35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Treatment: Drugs: Placebo
Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival was defined as the time from the date of randomization to the date of death for participants. If a participant discontinued study medication for reasons other than radiologic disease progression, the participant was followed for tumor response until radiologic disease progression or initiation of new anticancer therapy.
Query!
Timepoint [1]
0
0
Every 8 weeks, up to 12 months after the last participant was randomized or until the target number of events (deaths) was met, whichever was later. (Overall survival data was collected till 24 Jan 2014 which was date of observation of the 571st death)
Query!
Secondary outcome [1]
0
0
Progression-free Survival
Query!
Assessment method [1]
0
0
Tumor assessments were performed throughout the study based on RECIST, Version 1.1, 2009. Progression free survival was defined as the time (in months) from the date of randomization until the date of the investigator-assessed radiological disease progression or death due to any cause. For participants who were alive with no radiological disease progression as of the analysis cut-off date, their survival was censored at the date of the last tumor assessment. Participants who received non-study cancer treatment before disease progression, or participants with clinical but not radiologic evidence of progression, were censored at the date of the last radiologic evaluable tumor assessment before the non-study cancer treatment was initiated.
Query!
Timepoint [1]
0
0
Every 8 weeks, up to 12 months after the last participant was randomized or until the date of the investigator-assessed radiological disease progression or death due to any cause,whichever was later. (Progression free survival cutoff: 31 Jan 2014)
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Adverse Events (AE), Treatment-Related AEs, Discontinuations, Serious Adverse Events (SAEs) and Deaths
Query!
Assessment method [2]
0
0
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-related AEs were events between administration of study drug and up to 30 Days that were absent before treatment or that worsened relative to pre-treatment state. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability /incapacity; congenital anomaly. The AEs were graded for severity using National Cancer Institute Common Terminology Criteria for AEs.
Query!
Timepoint [2]
0
0
From the time of signing the informed consent form until the period of participant follow up (30 days following after the administration of last dose of study medication or until initiation of new antitumor therapy, whichever was earlier
Query!
Eligibility
Key inclusion criteria
1. Has provided written informed consent
2. Has adenocarcinoma of the colon or rectum
3. Has failed at least 2 prior regimens of standard chemotherapies for metastatic
colorectal cancer
4. ECOG performance status of 0 or 1
5. Is able to take medications orally
6. Has adequate organ function (bone marrow, kidney and liver)
7. Women of childbearing potential must have a negative pregnancy test and must agree to
adequate birth control if conception is possible. Males must agree to adequate birth
control.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Certain serious illnesses or medical condition(s)
2. Has had certain other recent treatment e.g. major surgery, anticancer therapy,
extended field radiation, received investigational agent, within the specified time
frames prior to study drug administration
3. Has received TAS-102
4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any
prior therapies
5. Is a pregnant or lactating female
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/06/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
23/05/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
800
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Royal North Shore Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
The Queen Elisabeth Hospital - Woodville South
Query!
Recruitment hospital [3]
0
0
Austin Hospital - Heidelberg
Query!
Recruitment hospital [4]
0
0
The Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [5]
0
0
Sir Charles Gairdner Hospital - Perth
Query!
Recruitment postcode(s) [1]
0
0
2065 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [5]
0
0
6009 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Indiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Louisiana
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Massachusetts
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Missouri
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New Hampshire
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Ohio
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Virginia
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Linz
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Wels
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Wien
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Brussels
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Charleroi
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Edegem
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Gent
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Leuven
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Hradec Kralove
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Nova Ves pod Plesi
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Besancon
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Bordeaux
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Lille
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Montpellier
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Paris cedex 12
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Rennes cedex
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Berlin
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Bonn
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Dresden
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Frankfurt
Query!
Country [34]
0
0
Germany
Query!
State/province [34]
0
0
Halle (Saale)
Query!
Country [35]
0
0
Germany
Query!
State/province [35]
0
0
Hamburg
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Koeln
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Mainz
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Mannheim
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Muenchen
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
München
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Oldenburg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Ulm
Query!
Country [43]
0
0
Ireland
Query!
State/province [43]
0
0
Cork
Query!
Country [44]
0
0
Ireland
Query!
State/province [44]
0
0
Dublin
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Lombardy
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Genova
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Milano
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Milan
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Naples
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Napoli
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Orbassano
Query!
Country [52]
0
0
Italy
Query!
State/province [52]
0
0
Pisa
Query!
Country [53]
0
0
Italy
Query!
State/province [53]
0
0
Reggio Emilia
Query!
Country [54]
0
0
Italy
Query!
State/province [54]
0
0
Rimini
Query!
Country [55]
0
0
Italy
Query!
State/province [55]
0
0
Sondrio
Query!
Country [56]
0
0
Japan
Query!
State/province [56]
0
0
Aichi
Query!
Country [57]
0
0
Japan
Query!
State/province [57]
0
0
Chiba
Query!
Country [58]
0
0
Japan
Query!
State/province [58]
0
0
Ehime
Query!
Country [59]
0
0
Japan
Query!
State/province [59]
0
0
Hokkaido
Query!
Country [60]
0
0
Japan
Query!
State/province [60]
0
0
Hyogo
Query!
Country [61]
0
0
Japan
Query!
State/province [61]
0
0
Ibaraki
Query!
Country [62]
0
0
Japan
Query!
State/province [62]
0
0
Kanagawa
Query!
Country [63]
0
0
Japan
Query!
State/province [63]
0
0
Osaka
Query!
Country [64]
0
0
Japan
Query!
State/province [64]
0
0
Saitama
Query!
Country [65]
0
0
Japan
Query!
State/province [65]
0
0
Shizuoka
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Tochigi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Tokyo
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Fukuoka
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Kumamoto
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Tokushima
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Barcelona
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Lleida
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Madrid
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Malaga
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Murcia
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Sabadell
Query!
Country [77]
0
0
Spain
Query!
State/province [77]
0
0
Sevilla
Query!
Country [78]
0
0
Spain
Query!
State/province [78]
0
0
Valencia
Query!
Country [79]
0
0
Sweden
Query!
State/province [79]
0
0
Stockholm
Query!
Country [80]
0
0
Sweden
Query!
State/province [80]
0
0
Uppsala
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Aberdeen
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Bristol
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Leeds
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
London
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
Surrey
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Taiho Oncology, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to compare the efficacy and safety of TAS-102 versus placebo in
patients with refractory metastatic colorectal cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01607957
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
From - Boston, MA
Query!
Address
0
0
Dana-Farber Cancer Institute
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01607957
Download to PDF